BCRX into Earnings: Shorts Retreat as Momentum Builds

BioCryst Pharmaceuticals heads into its Q3 earnings release, due after the close tomorrow, with short sellers markedly less aggressive than six weeks ago and options traders showing little defensiveness despite the binary event ahead.

The most striking feature of the positioning picture is the scale of short covering since early October. Short interest has fallen from roughly 36 million shares at the start of October to 25.5 million now, a drop of around 27% in one month, taking the short position from well above 16% of the float down to 12.1%. That is still a meaningful short base for a mid-cap biotech, but the direction of travel has been sharply lower. The borrow market tells a consistent story: availability is running at 873% of outstanding short interest, meaning lenders hold roughly nine times as many shares available as are currently borrowed, the pool is nowhere near stressed. Cost to borrow has drifted slightly higher over the past week to 0.56%, though it remains well inside the range of the past 30 days and carries no urgency signal. Options positioning is similarly relaxed. The put/call ratio at 0.14 is barely above its 20-day average and sits close to the bottom of its 52-week range. Ahead of an earnings print, that is a notably unbothered read from the options market.

The Street reflects a tension that the positioning does not fully capture. The mean analyst price target at roughly $20.55 implies nearly 140% upside to the current $8.57 close, yet the stock has gone nowhere near that level, and several recent moves have been downward revisions. RBC Capital downgraded the stock to Sector Perform in September and cut its target to $11, the most bearish move among recent changes. JP Morgan, reinstated at Neutral in July with a $12 target, raised that modestly to $13 in late September. At the more constructive end, Needham holds its Buy and $16 target, while Cantor Fitzgerald and HC Wainwright sit at $29 and $32, respectively, though those latter two targets are from June and carry a degree of staleness. The bull case rests on Orladeyo's continued growth, $158M in second-quarter sales, up 10% year on year, alongside navenibart as a potential longer-interval prophylactic that could widen the HAE franchise. Bears focus on competition from Takhzyro and CSL Behring, the risk of needing external capital, and uncertainty around both Netherton Syndrome and avoralstat. Valuation is complicated: the EV/EBITDA multiple at 17.4x has compressed by roughly four turns over the past 30 days as operating profit has improved, and the earnings yield factor ranks at the 97th percentile of the ORTEX universe, an unusual read for a company still building toward consistent profitability.

One real-economy data point adds texture without being predictive. Medicaid reimbursements for BioCryst drugs ran 18% above the same quarter a year earlier in the most recently available quarter, covering Q1 2026, reaching approximately $17.4M in Medicaid dollars reimbursed. That dataset has not been shown to lead the company's reported revenue figures, so it cannot be called a leading indicator, but it confirms the drug is reaching government-covered patients and that reimbursement volumes are growing. Separately, retail attention to BioCryst on Wikipedia and the ORTEX platform has picked up, with a z-score of 1.9 against the stock's own 90-day history, the highest level in the recent window, suggestive of renewed investor focus ahead of the print.

Institutional ownership gives additional context on who is holding through the event. BlackRock added 1.24 million shares in Q3 and now reports 9.4% of the company. State Street added nearly 3 million shares in the same quarter to reach 5.9%. Both are index-driven additions that follow the company's improved market cap trajectory, but the size of the State Street increase is notable. Deerfield, a specialist healthcare manager, holds 5.9% and was flat as of its last filing. RA Capital, another healthcare-focused fund with 6.2%, trimmed modestly from 7.3% previously. No holder has filed a 13D activist position; all 13D/G filings are passive in intent. As always, these stakes are as last disclosed around the 5% threshold, and holders who drop below that level may not file again.

The stock gained 5.8% over the past week to $8.57, bucking weakness across most of its correlated peers: RIGL fell 3.3% and KYTX dropped 8.3% in the same period, while MDGL lost nearly 10%. The most comparable post-earnings reaction in the history available is August 2026, when BCRX rose 3.1% the day after results and extended to a 17.4% gain over the following five sessions. The setup into tomorrow's close, with shorts having already retreated substantially and borrow conditions loose, leaves the question less about squeeze dynamics and more about whether the revenue trajectory on Orladeyo and any update on navenibart's commercial path can sustain the momentum that has separated BCRX from its peer group through the autumn.